Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2005-02-04
2009-12-01
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S141100, C424S130100, C424S009340, C424S234100, C424S184100, C424S178100, C424S236100, C424S247100, C536S023100
Reexamination Certificate
active
07625559
ABSTRACT:
Antibodies that specifically bind to toxins ofC. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
REFERENCES:
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 6214341 (2001-04-01), Thomas, Jr. et al.
patent: 7151159 (2006-12-01), Von Eichel-Streiber et al.
patent: WO 92/03918 (1992-03-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO-99/12971 (1999-03-01), None
patent: WO-99/20304 (1999-04-01), None
patent: WO-01/92340 (2001-12-01), None
patent: WO-03/092630 (2003-11-01), None
Greenspan et al. (Nature Biotechnology 17: 936-937, 1999).
Seffernick et al (J. Bacteriology, 2001; 183: 2405-2410).
Bowie et al. (Science, 1990, 257:1306-1310).
Aboud, W., et al. “Pseudomembranous colitis.”Gastrointest Endosc. Aug. 2000; 52(2):234.
Adler, S., et al. “Costs of low-temperature plasma sterilization compared with other sterilization methods.”J Hosp Infect. Oct. 1998; 40(2):125-34.
Aktories, K., et al. “Rho GTPases as targets of bacterial protein toxins.”Biol Chem. May-Jun. 2000; 381(5-6):421-6.
Aldeen, W.E., et al. “Comparison of the TOX A/B test to a cell culture cytotoxicity assay for the detection ofClostridium difficilein stools.”Diagn Microbiol Infect Dis. Apr. 2000; 36(4):211-3.
Alfa, M.J., et al. “Characterization of a toxin A-negative, toxin B-positive strain ofClostridium difficileresponsible for a nosocomial outbreak ofClostridium difficile-associated diarrhea.”J Clin Microbiol. Jul. 2000; 38(7):2706-14.
Anderson, R.J., et al. “Evidence for Rho protein regulation of renal tubular epithelial cell function.”Kidney Int. Nov. 2000; 58(5):1996-2006.
Aronsson, B., et al. “Enzyme-linked immunosorbent assay (ELISA) for antibodies toClostridium difficiletoxins in patients with pseudomembranous colitis and antibiotic-associated diarrhoea.”J Immunol Methods. Jun. 10, 1983; 60(3):341-50.
Aronsson, B., et al. “Diagnosis and epidemiology ofClostridium difficileenterocolitis in Sweden.”J Antimicrob Chemother. Dec. 1984; 14 Suppl D:85-95.
Bacon, Ill, A.E., etal. “Immunoglobulin G directed against toxins A and B ofClostridium difficilein the general population and patients with antibiotic-associated diarrhea.”Diagn Microbiol Infect Dis. Apr. 1994; 18(4):205-9.
Barbut, F., et al. “Antimicrobial susceptibilities and serogroups of clinical strains ofClostridium difficileisolated in France in 1991 and 1997.”Antimicrob Agents Chemother. Nov. 1999; 43(11):2607-11.
Barroso, L.A., et al. “Nucleotide sequence ofClostridium difficiletoxin B gene.”Nucleic Acids Res. Jul. 11, 1990; 18(13):4004.
Barth, H., et al. “Low pH-induced formation of ion channels byclostridium difficiletoxin B in target cells.”J Biol Chem. Apr. 6, 2001; 276(14):10670-6.
Bartlett, J.G., et al. “Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing Clostridia.”Am J Vet Res. Sep. 1978; 39(9):1525-30.
Bartlett, J.G., et al. “Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.”N Engl J Med. Mar. 9, 1978; 298(10):531-4.
Bartlett, J.G., et al. “Comparison of five regimens for treatment of experimental clindamycin- associated colitis.”J Infect Dis. Jul 1978; 138(1):81-6.
Bartlett, J.G., et al. “Colitis induced byClostridium difficile.”Rev Infect Dis. Mar.-Apr. 1979; 1(2):370-8.
Bartlett, J.G. “Treatment of antibiotic-associated pseudomembranous colitis.”Rev Infect Dis. Mar.-Apr. 1984; 6 Suppl 1:S235-41.
Berdoz, J., et al. “In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells.”Proc Natl Acad Sci USA. Mar. 16, 1999; 96(6):3029-34.
Berneman, A., et al. “The specificity patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions.”Infect lmmun. Sep. 1998; 66(9):4163-8.
Bongaerts, G.P.A., et al. “Role of toxins A and B in the pathogenesis ofClostridium difficiledisease.”Microb Pathog. Jul 1994; 17(1):1-12.
Boquet, P. “Bacterial toxins inhibiting or activating small GTP-binding proteins.”Ann N Y Acad Sci. 1999; 886:83-90.
Borody, T.J. ““Flora Power” —fecal bacteria cure chronicC. difficilediarrhea.”Am J Gastroenterol. Nov. 2000; 95(11):3028-9.
Borriello, S.P. “Pathogenesis ofClostridium difficileinfection.”J Antimicrob Chemother. May 1998; 41 Suppl C:13-9.
Borriello, S.P., et al. “Clostridium difficileinfections of the gut: the unanswered questions.”J Antimicrob Chemother. May 1998; 41 Suppl C:67-9.
Borriello, S.P., et al. “Clostridium difficile-a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis.”J Med Microbiol. Aug. 1987; 24(1):53-64.
Busch, C., et al. “Involvement of a conserved tryptophan residue in the UDP-glucose binding of large clostridial cytotoxin glycosyltransferases.”J Bio! Chem. May 5, 2000; 275(18): 13228-34.
Calderón, G.M., et al. “Effects of toxin A fromClostridium difficileon mast cell activation and survival.”Infect Immun. Jun. 1998; 66(6):2755-61.
Castagliuolo, I., et al. “Clostridium difficiletoxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells.”J lmmunol. Jun. 15, 1998; 160(12): 6039-45.
Castagliuolo, I., et al. “Saccharomyces boulardiiprotease inhibits the effects ofClostridium difficiletoxins A and B in human colonic mucosa.”Infect lmmun. Jan. 1999; 67(1):302-7.
Castagliuolo, I., et al. “A receptor decoy inhibits the enterotoxic effects ofClostridium difficiletoxin A in rat ileum.”Gastroenterology. Aug. 1996; 111(2):433-8.
Castagliuolo, I., et al. “IL-11 inhibitsClostridium difficiletoxin A enterotoxicity in rat ileum.”Am J Physiol. Aug. 1997; 273(2 Pt 1):G333-41.
Cerquetti, M., et al. “Characterization of surface layer proteins from differentClostridium difficileclinical isolates.”Microb Pathog. Jun. 2000; 28(6):363-72.
Chang, T-W, et al. “Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients.”Infect lmmun. May 1978; 20(2):526-9.
Chang, T-W, et al. “Neutralization ofClostridium difficiletoxin byClostridium sordelliiantitoxins.”Infect lmmun. Nov. 1978; 22(2):418-22.
Chang, T-W, et al. “Cytotoxicity assay in antibiotic-associated colitis.”J Infect Dis. Nov. 1979; 140(5):765-70.
Chaves-Olarte, E., et al. “A novel cytotoxin fromClostridium difficileserogroup F is a functional hybrid between two other large clostridial cytotoxins.”J Biol Chem. Apr. 16, 1999; 274(16): 11046-52.
Chaves-Olarte, E., et al. “Toxins A and B fromClostridium difficilediffer with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells.”J Clin Invest. Oct. 1, 1997; 100(7):1734-41.
Ciesla, Jr., W.P., et al. “Clostridium difficileoxins A and B are cation-dependent UDP-glucose hydrolases with differing catalytic activities.”J Biol Chem. Jun. 26, 1998; 273(26):16021-6.
Clabots, C.R., et al. “Acquisition ofClostridium difficileby hospitalized patients: evidence for colonized new admissions as a source of infection.”J Infect Dis. Sep. 1992; 166(3):561-7.
Cohen, S.H., et al. “
Ambrosino Donna
Babcock Gregory J.
Broering Teresa
Graziano Robert
Hernandez Hector Javier
DeConti, Jr. Esq. Giulio A.
Lahive & Cockfield LLP
Medarex Inc.
Mondesi Robert B
Remillard, Esq. Jane E.
LandOfFree
Antibodies against Clostridium difficile toxins and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against Clostridium difficile toxins and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against Clostridium difficile toxins and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149520